Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma.

ABSTRACT: The role of cytarabine-based induction and autologous stem cell transplantation (ASCT) in front-line treatment of younger patients with mantle cell lymphoma (MCL) is well established, however the utility of intensive approaches in older patients remains unclear. This retrospective study compared first line treatment outcomes in patients aged 60 years or more, treated at six tertiary centres between 2000-2015. 70 patients included had a median age of 69 (60-91) and most (94%) demonstrated advanced stage disease. Treatment regimens included: R-CHOP-like (n?=?39), alternating R-CHOP/R-DHAC (n?=?10), R-HyperCVAD/R-MA (n?=?7), R-CHOP/Cytarabine (Nordic Protocol) (n?=?10) and other (n?=?4). 16 patients underwent an ASCT. The median follow-up for surviving patients was 37 months. Compared to R-CHOP-like therapies, cytarabine-based regimens were associated with an improved overall response rate (ORR) of 70% vs 33% (p?

SUBMITTER: Ratnasingam S 

PROVIDER: S-EPMC6753133 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature